Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2014

Open Access 01-12-2014 | Case report

Colonic stenosis caused by infection of an intraperitoneal access port system: a rare complication of intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis

Authors: Jun Kinoshita, Sachio Fushida, Tomoya Tsukada, Katsunobu Oyama, Toshifumi Watanabe, Koichi Okamoto, Isamu Makino, Keishi Nakamura, Hironori Hayashi, Hisatoshi Nakagawara, Tomoharu Miyashita, Hidehiro Tajima, Hiroyuki Takamura, Itasu Ninomiya, Hirohisa Kitagawa, Takashi Fujimura, Tetsuo Ohta

Published in: World Journal of Surgical Oncology | Issue 1/2014

Login to get access

Abstract

Background

Intraperitoneal (IP) chemotherapy is garnering attention as an effective treatment for gastric cancer with peritoneal metastasis. We report the case of a patient who developed colonic stenosis caused by infection of an IP access port system during IP chemotherapy. It was difficult to differentiate whether the extrinsic colonic stenosis arose from a catheter infection or peritoneal metastasis of the gastric cancer.

Case presentation

A 66-year-old Japanese man underwent total gastrectomy for gastric cancer. Because the intraoperative findings revealed peritoneal metastasis, a port system was implanted for subsequent IP chemotherapy. Two months after initiation of chemotherapy, he complained of vomiting and abdominal pain. A computed tomography scan revealed marked thickening of the sigmoid colon wall adjacent to the catheter of the IP access port system. A barium enema demonstrated extrinsic irregular stenosis of the sigmoid colon. Although it was difficult to distinguish whether infection or peritoneal metastasis had caused the colonic stenosis, we removed the port system to obtain a therapeutic diagnosis. Coagulase-negative staphylococci were detected by catheter culture. The wall thickening and stenosis of the sigmoid colon completely resolved after removal of the port system.

Conclusions

We report the case of a rare complication in association with an IP access port system. Infection of the port system should be considered as a differential diagnosis when colonic stenosis adjacent to the catheter is observed during IP chemotherapy.
Appendix
Available only for authorised users
Literature
1.
go back to reference Siewert JR, Bottcher K, Roder JD, Busch R, Hermanek P, Meyer HJ: Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg. 1993, 80: 1015-1018. 10.1002/bjs.1800800829.CrossRefPubMed Siewert JR, Bottcher K, Roder JD, Busch R, Hermanek P, Meyer HJ: Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group. Br J Surg. 1993, 80: 1015-1018. 10.1002/bjs.1800800829.CrossRefPubMed
2.
go back to reference Allum WH, Powell DJ, McConkey CC, Fielding JW: Gastric cancer: a 25-year review. Br J Surg. 1989, 76: 535-540. 10.1002/bjs.1800760604.CrossRefPubMed Allum WH, Powell DJ, McConkey CC, Fielding JW: Gastric cancer: a 25-year review. Br J Surg. 1989, 76: 535-540. 10.1002/bjs.1800760604.CrossRefPubMed
3.
go back to reference Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M: Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a gynecologic oncology group pilot study. J Clin Oncol. 1995, 13: 2961-2967.PubMed Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M: Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a gynecologic oncology group pilot study. J Clin Oncol. 1995, 13: 2961-2967.PubMed
4.
go back to reference Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC, Gynecologic Oncology Group: Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum. J Clin Oncol. 1998, 16: 2620-2624.PubMed Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC, Gynecologic Oncology Group: Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum. J Clin Oncol. 1998, 16: 2620-2624.PubMed
5.
go back to reference Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA, Gynecologic Oncology Group: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006, 354: 34-43. 10.1056/NEJMoa052985.CrossRefPubMed Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA, Gynecologic Oncology Group: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006, 354: 34-43. 10.1056/NEJMoa052985.CrossRefPubMed
6.
go back to reference Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, Kamei T, Soma D, Miyato H, Yamashita H, Nagawa H: Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010, 21: 67-70. 10.1093/annonc/mdp260.CrossRefPubMed Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, Kamei T, Soma D, Miyato H, Yamashita H, Nagawa H: Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010, 21: 67-70. 10.1093/annonc/mdp260.CrossRefPubMed
7.
go back to reference Fushida S, Kinoshita J, Kaji M, Hirono Y, Goda F, Yagi Y, Oyama K, Sudo Y, Watanabe Y, Fujimura T: Society for study of peritoneal carcinomatosis in gastric cancer: phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2013, 71: 1265-1272. 10.1007/s00280-013-2122-0.PubMedCentralCrossRefPubMed Fushida S, Kinoshita J, Kaji M, Hirono Y, Goda F, Yagi Y, Oyama K, Sudo Y, Watanabe Y, Fujimura T: Society for study of peritoneal carcinomatosis in gastric cancer: phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2013, 71: 1265-1272. 10.1007/s00280-013-2122-0.PubMedCentralCrossRefPubMed
8.
go back to reference Fujiwara Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Mori M, Doki Y: Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. J Surg Oncol. 2012, 105: 38-42. 10.1002/jso.22057.CrossRefPubMed Fujiwara Y, Takiguchi S, Nakajima K, Miyata H, Yamasaki M, Kurokawa Y, Mori M, Doki Y: Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. J Surg Oncol. 2012, 105: 38-42. 10.1002/jso.22057.CrossRefPubMed
9.
go back to reference Imano M, Yasuda A, Itoh T, Satou T, Peng YF, Kato H, Shinkai M, Tsubaki M, Chiba Y, Yasuda T, Imamoto H, Nishida S, Takeyama Y, Okuno K, Furukawa H, Shiozaki H: Phase II study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis. J Gastrointest Surg. 2012, 16: 2190-2196. 10.1007/s11605-012-2059-3.CrossRefPubMed Imano M, Yasuda A, Itoh T, Satou T, Peng YF, Kato H, Shinkai M, Tsubaki M, Chiba Y, Yasuda T, Imamoto H, Nishida S, Takeyama Y, Okuno K, Furukawa H, Shiozaki H: Phase II study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis. J Gastrointest Surg. 2012, 16: 2190-2196. 10.1007/s11605-012-2059-3.CrossRefPubMed
10.
go back to reference Topuz E, Saip P, Aydiner A, Salihoglu Y, Aydin Y, Topuzlu C: Catheter complications associated with intraperitoneal chemotherapy. Eur J Gynaecol Oncol. 1998, 19: 275-279.PubMed Topuz E, Saip P, Aydiner A, Salihoglu Y, Aydin Y, Topuzlu C: Catheter complications associated with intraperitoneal chemotherapy. Eur J Gynaecol Oncol. 1998, 19: 275-279.PubMed
11.
go back to reference Topuz E, Salihoglu Y, Aydiner A, Saip P, Tas F, Sozen T, Berkman S, Bengisu E: Celsite port and catheter as an intraperitoneal access device in the treatment of ovarian cancer. J Surg Oncol. 2000, 74: 223-226. 10.1002/1096-9098(200007)74:3<223::AID-JSO14>3.0.CO;2-Q.CrossRefPubMed Topuz E, Salihoglu Y, Aydiner A, Saip P, Tas F, Sozen T, Berkman S, Bengisu E: Celsite port and catheter as an intraperitoneal access device in the treatment of ovarian cancer. J Surg Oncol. 2000, 74: 223-226. 10.1002/1096-9098(200007)74:3<223::AID-JSO14>3.0.CO;2-Q.CrossRefPubMed
12.
go back to reference Piccart MJ, Speyer JL, Markman M, ten Bokkel Huinink WW, Alberts D, Jenkins J, Muggia F:Intraperitoneal chemotherapy: technical experience at five institutions. Semin Oncol. 1985, 12: 90-96.PubMed Piccart MJ, Speyer JL, Markman M, ten Bokkel Huinink WW, Alberts D, Jenkins J, Muggia F:Intraperitoneal chemotherapy: technical experience at five institutions. Semin Oncol. 1985, 12: 90-96.PubMed
13.
go back to reference Davidson SA, Rubin SC, Markman M, Jones WB, Hakes TB, Reichman B, Almadrones L, Chapman D, Lewis JL, Hoskins WJ: Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system. Gynecol Oncol. 1991, 41: 101-106. 10.1016/0090-8258(91)90266-8.CrossRefPubMed Davidson SA, Rubin SC, Markman M, Jones WB, Hakes TB, Reichman B, Almadrones L, Chapman D, Lewis JL, Hoskins WJ: Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system. Gynecol Oncol. 1991, 41: 101-106. 10.1016/0090-8258(91)90266-8.CrossRefPubMed
14.
go back to reference Malmstrom H, Carstensen J, Simonsen E: Experience with implanted subcutaneous ports for intraperitoneal chemotherapy in ovarian cancer. Gynecol Oncol. 1994, 54: 27-34. 10.1006/gyno.1994.1161.CrossRefPubMed Malmstrom H, Carstensen J, Simonsen E: Experience with implanted subcutaneous ports for intraperitoneal chemotherapy in ovarian cancer. Gynecol Oncol. 1994, 54: 27-34. 10.1006/gyno.1994.1161.CrossRefPubMed
15.
go back to reference Makhija S, Leitao M, Sabbatini P, Bellin N, Almadrones L, Leon L, Spriggs DR, Barakat R: Complications associated with intraperitoneal chemotherapy catheters. Gynecol Oncol. 2001, 81: 77-81. 10.1006/gyno.2000.6108.CrossRefPubMed Makhija S, Leitao M, Sabbatini P, Bellin N, Almadrones L, Leon L, Spriggs DR, Barakat R: Complications associated with intraperitoneal chemotherapy catheters. Gynecol Oncol. 2001, 81: 77-81. 10.1006/gyno.2000.6108.CrossRefPubMed
16.
go back to reference Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, Clarke-Pearson D: Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 2006, 100: 27-32. 10.1016/j.ygyno.2005.11.013.CrossRefPubMed Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, Clarke-Pearson D: Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a gynecologic oncology group study. Gynecol Oncol. 2006, 100: 27-32. 10.1016/j.ygyno.2005.11.013.CrossRefPubMed
17.
go back to reference Braly P, Doroshow J, Hoff S: Technical aspects of intraperitoneal chemo- therapy in abdominal carcinomatosis. Gynecol Oncol. 1986, 25: 319-333. 10.1016/0090-8258(86)90083-1.CrossRefPubMed Braly P, Doroshow J, Hoff S: Technical aspects of intraperitoneal chemo- therapy in abdominal carcinomatosis. Gynecol Oncol. 1986, 25: 319-333. 10.1016/0090-8258(86)90083-1.CrossRefPubMed
18.
go back to reference Pfeifle CE, Howell SB, Markman M, Lucas WE: Totally implantable system for peritoneal access. J Clin Oncol. 1984, 2: 1277-1280.PubMed Pfeifle CE, Howell SB, Markman M, Lucas WE: Totally implantable system for peritoneal access. J Clin Oncol. 1984, 2: 1277-1280.PubMed
19.
go back to reference Emoto S, Ishigami H, Hidemura A, Yamaguchi H, Yamashita H, Kitayama J, Watanabe T: Complications and management of an implanted intraperitoneal access port system for intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Jpn J Clin Oncol. 2012, 42: 1013-1019. 10.1093/jjco/hys129.CrossRefPubMed Emoto S, Ishigami H, Hidemura A, Yamaguchi H, Yamashita H, Kitayama J, Watanabe T: Complications and management of an implanted intraperitoneal access port system for intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Jpn J Clin Oncol. 2012, 42: 1013-1019. 10.1093/jjco/hys129.CrossRefPubMed
20.
go back to reference Alberts DS, Markman M, Armstrong D, Rothenberg ML, Muggia F, Howell SB: Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come!. J Clin Oncol. 2002, 20: 3944-3946.PubMed Alberts DS, Markman M, Armstrong D, Rothenberg ML, Muggia F, Howell SB: Intraperitoneal therapy for stage III ovarian cancer: a therapy whose time has come!. J Clin Oncol. 2002, 20: 3944-3946.PubMed
Metadata
Title
Colonic stenosis caused by infection of an intraperitoneal access port system: a rare complication of intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis
Authors
Jun Kinoshita
Sachio Fushida
Tomoya Tsukada
Katsunobu Oyama
Toshifumi Watanabe
Koichi Okamoto
Isamu Makino
Keishi Nakamura
Hironori Hayashi
Hisatoshi Nakagawara
Tomoharu Miyashita
Hidehiro Tajima
Hiroyuki Takamura
Itasu Ninomiya
Hirohisa Kitagawa
Takashi Fujimura
Tetsuo Ohta
Publication date
01-12-2014
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-12-177

Other articles of this Issue 1/2014

World Journal of Surgical Oncology 1/2014 Go to the issue